Another RIPK1 inhibitor, SIR-2446 is an oral RIPK1 inhibitor being developed by Sironax therapeutics for the treatment of AD and MS and is currently in Phase 1 clinical trials. Here, RIPK1 is linked to Alzheimer disease.